Goodwin Procter LLP advised Repertoire Immune Medicines on the deal. Repertoire Immune Medicines announced the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s...
You must be a Standard 1 Year member to access this content.
Cassels acted as Canadian counsel for Glass House in the transaction while Goodwin Procter LLP advised Mercer Park Brand Acquisition Corp. On April 8, 2021, Mercer...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Century Bancorp, Inc. on the deal, while Simpson Thacher advised J.P. Morgan Securities LLC as financial advisor to Eastern Bankshares. Century Bancorp,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Sentenial Limited on the deal. EML Payments was represented by Arthur Cox and Herbert Smith Freehills LLP. Sentenial Limited announced its sale to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Ares Management Corporation on the deal. Ares Management Corporation (NYSE: ARES) announced the formation of its Ares U.S. Real Estate Opportunity Fund III,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter, Fried Frank and Appleby advised LumiraDx Limited on the deal, while Sidley Austin LLP acted for CA Healthcare Acquisition Corp. LumiraDx Limited announced its...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Dotmatics, while Willkie Farr & Gallagher LLP advised Insightful Science on the deal. Insightful Science, a leading software provider serving the global...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised OPSWAT, Paul, Weiss advised Brighton Park Capital on the deal. OPSWAT announced its $125 million growth investment from Brighton Park Capital. OPSWAT plans...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Leaf Group Ltd. on the deal. Leaf Group Ltd. (NYSE: LEAF) announced its definitive merger agreement with Graham Holdings Company (NYSE: GHC)...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised the underwriters on the deal. ThredUp Inc. (thredUP) announced the pricing of its initial public offering of 12,000,000 shares of...
You must be a Standard 1 Year member to access this content.
